Yazarlar : Walter RB, Medeiros BC, Powell BL, Schiffer CA, Appelbaum FR, Estey EH.

Yayın : Haematologica.

Yayın Yılı : 2011

Pubmed Linki : http://www.ncbi.nlm.nih.gov/pubmed/22133771

Konu : Geriyatrik Hematoloji

Literatür İçeriği :  

Abstract

Histone deacetylase inhibitors such as vorinostat enhance gemtuzumab ozogamicin efficacy in vitro. We therefore investigated vorinostat+gemtuzumab ozogamicin for adults ≥60 years with untreated acute myeloid leukemia. We stratified patients into 2 groups (group 1: patients aged ≥70 years and performance status 2-3; group 2: aged 60-69 years with performance status 0-3 or aged ≥70 years and performance status 0-1), and monitored responses separately in group 2 patients with normal or favorable cytogenetics (group 2A) and other cytogenetics (group 2B). Among 31 patients, 6 (19.4%) achieved complete remission, and 1 (3.2%) achieved complete remission with incomplete platelet recovery; these patients had a superior median overall survival than non-responders (553 vs. 131 days, p=0.0026). Response rates were: group 1, 1/10 (10.0%); group 2A, 6/13 (46.2%); and group 2B, 0/8 (0%). These data indicate that vorinostat+gemtuzumab ozogamicin has activity that is mostly confined to patients with normal karyotype disease. ClinicalTrial.gov: NCT00673153.

Literatür Arşivi